Papers
2
Total Citations
41
H-Index
2
About
Alex Freeman is an emerging surgical oncologist and clinical trialist whose research is reshaping the technical and pathological landscape of prostate cancer surgery. Freeman's work centers on intraoperative margin assessment during robot-assisted radical prostatectomy (RARP), with a particular focus on preserving patients' quality of life through nerve-sparing techniques. His most celebrated contribution is the NeuroSAFE PROOF trial — a landmark multicentre, randomised phase 3 study published in 2025 — which rigorously evaluated the NeuroSAFE frozen section technique as a real-time tool for detecting positive surgical margins, enabling surgeons to make critical intraoperative decisions that improve postoperative erectile function and urinary continence recovery. Already accumulating 39 citations within its publication year, the trial has rapidly established itself as a significant reference point in urological oncology. Building on this foundation, Freeman is pioneering the next generation of margin assessment through the LaserSAFE feasibility study, exploring confocal laser microscopy as a novel alternative to frozen section analysis. His trajectory suggests a researcher committed to translating cutting-edge diagnostic technology into meaningful clinical outcomes for men undergoing prostate cancer surgery.
Research Focus
Key Achievements
Top Papers
- 1
- 2